The role of the neuromodulators in the preventive treatment of migraine;Papel de los neuromoduladores en el tratamiento preventivo de la migraña

Revista de Neurologia

Volumn 49, Issue 1, 2009, Pages 25-32

  Pascual Gómez, Julio ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Gabapentin; Levetiracetam; Migraine; Neuromodulators; Topiramate; Valproic acid; Zonisamide

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ACIDOSIS; ALOPECIA; ANALGESIA; ATAXIA; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; EPILEPTIC AURA; GLAUCOMA; HEADACHE; HUMAN; HYPERTHERMIA; HYPOTHERMIA; INSOMNIA; IRRITABILITY; LIVER TOXICITY; MIGRAINE; MIGRAINE AURA; NAUSEA; NAUSEA AND VOMITING; PANCREATITIS; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TRANSFORMED MIGRAINE; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 69349096054     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4901.2009293     Document Type: Review

References (52)

1. Pascual J, Combarros O, Leno C, Polo JM, Rebollo M, Berciano J. Distribución por diagnósticos del dolor de cabeza como motivo de consulta neurológica. Med Clin 1995; 104; 161-164
2. Menken M. Munsat TL, Toole JF. The global burden of disease study: implications for Neurology. Arch Neurol 2000; 57: 418-420 (Pubitemid 30140537)
3. Láinez JM, Leira J, Pascual J, Díez-Tejedor E, Morales F, Titus F, et al. Quality of life and migraine: a multicentre Spanish study. In Olesen J, Steiner TJ, Lipton RB, eds. Reducing the burden of headache. Frontiers of Headache Research, vol.11. Oxford: Oxford University Press; 2003. p. 148-152
4. Láinez JM, Monzón MJ, and the Spanish Occupational Migraine Study Group. The socio-economic impact of migraine in Spain. In Olesen J, Steiner TJ, Lipton RB, eds. Reducing the burden of headache. Frontiers of Headache Research, vol.11. Oxford: Oxford University Press; 2003. p 255-259
5. Pascual J. Migraña. Barcelona: Masson; 2001.
6. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001; 41: 638-645 (Pubitemid 32777746)
7. Pascual J, Aguirre J, García-Moncó JC, Seijo M. Migraña y cefalea de tensión. In Mateos V, ed. Guías para el diagnóstico y tratamiento de las cefaleas. Barcelona: Prous; 2006. p. 37-66.
8. Pascual J. Migraña: tratamiento preventivo. In Mateos V, Pareja JA, Pascual J, eds. Tratado de cefaleas. Madrid: Luzán; 2009. p. 131-150
9. Pascual J, Rivas MT. Migraña y epilepsia: ¿mecanismos fisiopatológicos comunes? In Mauri JA, Santos S, eds. Epilepsia y migraña. Madrid: Ergón; 2008. p. 33-42.
10. Kaniecki R. Neuromodulators for migraine prevention. Headache 2008; 48: 586-600.
11. Chronicle E, Mulleners W. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev 2004; 3: CD003226.
12. Freitag FG, Collins SD, Carlson HA, Goldstein J, Saper J, Silberstein S, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002; 58: 1652-1659 (Pubitemid 34602897)
13. Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997; 17: 103-108 (Pubitemid 27166264)
14. Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S, et al. Migraine prophylaxis with divalproex. Arch Neurol 1995; 52: 281-286
15. Silberstein SD. Divalproex sodium in headache: literature review and clinical guidelines. Headache 1996; 36: 547-555
16. Brandes J, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004; 291: 965-973 (Pubitemid 38543754)
17. Diener HC, Tfelt-Hansen P, Dahlof C, Láinez MJA, Sandrini G, Wang SJ, et al. Topiramate in migraine prophylaxis. Results from a placebo-controlled trail with propranolol as active control. J Neurol 2004; 251: 943-950 (Pubitemid 39119312)
18. Silberstein SD, Neto W, Schmitt JJ, Jacobs D. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004; 61: 490-495 (Pubitemid 38923736)
19. Silvestrini M, Bartolini M, Coccia M, Barufaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. Cephalalgia 2003; 23: 820-824
20. Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007; 47: 170-180 (Pubitemid 46246319)
21. Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ, TIPMAT-MIG 201 (TOP-CHROME) Study Group. Topiramate reduces headache days in chronic migraine: a randomized, doubleblind, placebo-controlled study. Cephalalgia 2007; 27: 814-823
22. Pascual J, Sánchez del Río M, Mateos V, Láinez JM, Hernández-Gallego J, Leira R, et al. Topiramate for patients with refractory migraine: an observational, multicenter study in Spain. Neurología 2004; 18: 364-367
23. Gracia-Naya M, Latorre-Jiménez AM, Ríos-Gómez C, Santos-Lasaosa S, Mauri JA, Sánchez-Valiente S, et al. Topiramato en la cefalea crónica diaria por migraña. Rev Neurol 2007; 45: 456-459 (Pubitemid 350292901)
24. Cacabelos P, El Berdei Y, Rivas MT, Riveira C, Conde A, Pascual J. Dosis bajas versus dosis altas de topiramato en el tratamiento preventivo de la migraña. Neurología 2009 [in press].
25. Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997; 17: 109-112 (Pubitemid 27166265)
26. D'Andrea G, Granella F, Cadaldini M, Manzoni GC. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study. Cephalalgia 1999; 19: 64-66 (Pubitemid 29136854)
27. Lampl C, Buzath A, Klinger D, Neuman K. Lamotrigine in the prophylactic treatment of migraine aura - a pilot study. Cephalalgia 1999; 19: 58-63. (Pubitemid 29136853)
28. Pascual J, Caminero AB, Mateos V, Roig C, Leira R, García- Moncó JC, et al. Preventing disturbing migraine aura with lamotrigine: an open study. Headache 2004; 44: 1024-1028 (Pubitemid 39532346)
29. Mathew NT. Gabapentin in migraine prophylaxis. Cephalalgia 1996; 16: 357.
30. Wessely P, Baumgartner C, Kingler D. Preliminary results of a double-blind study with the new migraine prophylactic drug gabapentin. Cephalalgia 1987; 7 (Suppl 6): 477-478
31. Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001; 41: 119-128
32. Di Trapani G, Mei D, Marra C, Mazza S, Capuano A. Gabapentin in the prophylaxis of migraine with and without aura. Cephalalgia 1997; 17: 109-112 (Pubitemid 127757205)
33. Krusz JC. Levetiracetam as prophylaxis for resistant headaches [abstract]. Cephalalgia 2001; 21: 373.
34. Drake ME Jr, Greathouse NI, Armentbright AD, Renner JB. Levetiracetam for preventive treatment of migraine [abstract]. Cephalalgia 2001; 21: 373.
35. Troost BT, Wiles RM. Levetiracetam for treatment of intractable headache. Headache 2003; 43: 588.
36. Brighina F, Palermo A, Aloisio A, Francolini M, Giglia G, Fierro B. Levetiracetam in the prophylaxis of migraine with aura: a 6-month open-label study. Clin Neuropharmacol 2006; 29: 338-342 (Pubitemid 44729945)
37. Pakalnis A, Kring D, Meier L. Levetiracetam prophylaxis in pediatric migraine. An open-label study. Headache 2007; 47: 427-430
38. Miller GS. Efficacy and safety of levetiracetam in pediatric migraine. Headache 2004; 44: 238-243
39. Frampton JE, Scott LJ. Zonisamide: a review of its use in the management of partial seizures in epilepsy. CNS Drugs 2005; 19: 347-367 (Pubitemid 40593608)
40. Drake ME Jr, Greathouse NI, Renner JB, Armentbright AD. Open-label zonisamide for refractory migraine. Clin Neuropharmacol 2004; 27: 278-280
41. Smith TR. Treatment of refractory chronic daily headache with zonisamide: a case series. Cephalalgia 2001; 21: 482.
42. Krusz JC. Zonisamide in the treatment of headache disorders [abstract]. Cephalalgia 2001; 21: 374-375
43. Ashkenazi A, Benlifer A, Korenblit J, Silberstein SD. Zonisamide for migraine prophylaxis in refractory patients. Cephalalgia 2006; 26: 1199-1202 (Pubitemid 44359340)
44. Pascual-Gómez J, Alañá-García M, Oterino A, Leira-Muiño R, Láinez-Andrés JM. Tratamiento preventive de la migraña crónica con zonisamida: un estudio en pacientes refractarios o intolerantes a topiramato. Rev Neurol 2008; 47: 449-451
45. Pakalnis A, Kring D. Zonisamide prophylaxis in refractory pediatric patients. Headache 2006; 46: 804-807
46. Lipton RB, Silberstein SD, Saper JR, Bigal ME, Goadsby PJ. Why headache treatment fails. Neurology 2003; 60: 1064-1070
47. Massiou H. Migraine medication attributes are important for patient compliance. Drugs Today 2003; 39 (Suppl D): 25-29 (Pubitemid 38280251)
48. MacGregor EA. The doctor and the migraine patient: improving compliance. Neurology 1997; 48 (Suppl 3): 16-20.
49. Rompel H, Bauermeister PW. Aetiology of migraine and prevention with carbamazepine: results of a double-blind, cross-over study. S Afr Med J 1970; 44: 75-80.
50. Anthony M, Lance JW, Somerville B. A comparative trial of pindolol, clonidine and carbamazepine in the interval therapy of migraine. Med J Aust 1972; 1: 1343-1346
51. Freitag FG, Diamond S, Diamond ML, Urban GJ, Pepper B, Moore K. The prophylaxis of migraine with the gaba-agonist, tiagabine: a clinical report. Headache 1999; 39: 354.
52. Stensrud P, Sjaastad O. Clonacepam in migraine prophylaxis. Headache 1979; 19: 333-334